Appendix 2.
Reviewer Relationships With Industry and Other Entities (Relevant)—2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease
| Peer Reviewer | Representation | Consultant | Speakers’ Bureau | Ownership/ Partnership/ Principal |
Personal Research | Institutional, Organizational, or Other Financial Benefit |
Expert Witness |
|---|---|---|---|---|---|---|---|
| Eric R. Bates | Official Reviewer—Board of Trustees | • Bristol-Myers
Squibb • Daiichi-Sankyo • Merck • Sanofi-aventis |
None | None | None | None | None |
| Mark A. Creager | Official Reviewer—ACCF/AHA Task Force on Practice Guidelines | • Genzyme | None | None | None | None | None |
| William R. Hiatt | Official Reviewer—AHA | None | None | None | • BMS/sanofi-aventis | None | None |
| Hani Jneid | Official Reviewer—AHA | None | None | None | None | None | None |
| Krishnaswami Vijayaraghavan | Official Reviewer—Board of Governors | • Daiichi-Sankyo | •
Sanofi-aventis • Novartis |
None | None | • Johnson &
Johnson* • Merck |
None |
| Gary Ansel | Organizational Reviewer—SCAI | • Bard • Boston Scientific* • Cordis/Johnson & Johnson* • ev3 |
• Cordis/Johnson & Johnson* | None | • Abbott/Guidant
Vascular • Boston Scientific* • Cook Medical* |
None | None |
| Yung-wei Chi | Organizational Reviewer—SVM | None | None | None | None | None | None |
| Michael Conte | Organizational Reviewer—SVS | None | None | None | None | None | None |
| Tony Das | Organizational Reviewer—SCAI | • Abbott Vascular* • Bard* • Boston Scientific • Cordis* |
None | None | None | None | None |
| Thomas Huber | Organizational Reviewer—SVS | None | None | None | None | • Abbott Vascular† • Cook† • Medtronic† |
None |
| John P. Reilly | Organizational Reviewer—SVM | None | • Cordis • Johnson & Johnson • Lilly/Daiichi-Sankyo* |
None | None | None | |
| Wael A. Saad | Organizational Reviewer—SIR | None | None | None | None | None | None |
| T. Gregory Walker | Organizational Reviewer—SIR | • Medtronic Endovascular | None | None | None | None | None |
| J. Dawn Abbott | Content Reviewer—ACCF PVD Committee | • Medtronic Endovascular | None | None | None | None | None |
| Jeffrey L. Anderson | Content Reviewer—ACCF/AHA Task Force on Practice Guidelines | None | None | None | None | None | None |
| Herbert D. Aronow | Content Reviewer—ACCF PVD Committee | • Medtronic Endovascular | None | None | None | None | None |
| Jeffrey Berger | Content Reviewer | None | None | None | None | None | None |
| Lee A. Green | Content Reviewer—ACCF/AHA Task Force on Performance Measures | None | None | None | None | None | None |
| John Gordon | Content Reviewer—Board of Governors | None | None | None | None | None | None |
| Norman R. Hertzer | Content Reviewer—2005 PAD Writing Committee | None | None | None | None | None | None |
| Courtney O. Jordan | Content Reviewer—ACCF Prevention Committee | None | None | None | None | None | None |
| Prakash Krishnan | Content Reviewer | None | None | None | None | None | None |
| Michael Mansour | Content Reviewer—Board of Governors | None | None | None | None | None | None |
| Issam D. Moussa | Content Reviewer—ACCF Interventional Scientific Council | None | None | None | None | None | None |
| Rahul Patel | Content Reviewer—2005 PAD Writing Committee | None | None | None | None | None | None |
| Pam N. Peterson | Content Reviewer—ACCF/AHA Task Force on Clinical Data Standards | None | None | None | None | None | None |
| John Rundback | Content Reviewer—2005 PAD Writing Committee | • ev3 | • Boston Scientific | None | None | None | None |
This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review and determined to be relevant. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review.
According to the ACCF/AHA, a person has a relevant relationship IF: (a) The relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or (b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or (c) the person or a member of the person's household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document.
Significant relationship.
No financial benefit.
ACCF indicates American College of Cardiology Foundation; AHA, American Heart Association; PAD, peripheral artery disease; PVD, peripheral vascular disease; SCAI, Society for Cardiovascular Angiography and Interventions; SIR, Society of Interventional Radiology; SVM, Society for Vascular Medicine; and SVS, Society for Vascular Surgery.